Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Glumetinib (SCC244), a Selective MET Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer Harboring MET-alterations

Next Previous
Trial Profile

A Phase Ib/II, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Glumetinib (SCC244), a Selective MET Inhibitor in Patients With Advanced Non-Small Cell Lung Cancer Harboring MET-alterations

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gumarontinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms GLORY
  • Sponsors Haihe Biopharma

Most Recent Events

  • 24 Jun 2024 According to a Haihe Pharmaceutical's media release, Ministry of Health, Labor and Welfare of Japan approved New Drug Application (NDA) of Gumarontinib (SCC244) for the treatment of unresectable advanced or recurrent non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping mutation based on results from this trial.
  • 22 Jun 2023 Results of this trial (n=79; The 12-month follow-up data), presented in a Haihe Pharmaceutical's media release.
  • 22 Jun 2023 According to a Haihe Pharmaceutical's media release, the company announced that FDA (NMPA) approved to obtain conditional approval for listing in China. This study supports the registration of Haiyitan.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top